Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells $6,388,491.01 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 235,477 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $27.13, for a total transaction of $6,388,491.01. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Liquidia Trading Up 3.0%

NASDAQ:LQDA traded up $0.77 during trading hours on Wednesday, reaching $26.68. The company’s stock had a trading volume of 6,960,401 shares, compared to its average volume of 2,033,381. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of 19.47 and a beta of 0.61. The firm has a 50-day simple moving average of $69.27 and a 200-day simple moving average of $62.07. Liquidia Corporation has a 1 year low of $21.94 and a 1 year high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the company earned ($0.49) earnings per share. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. Research analysts expect that Liquidia Corporation will post 2.1 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on LQDA shares. Jefferies Financial Group upgraded Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. Zacks Research lowered Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Wedbush set a $58.00 target price on shares of Liquidia in a report on Friday, October 2nd. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $30.00 target price (down from $108.00) on shares of Liquidia in a research note on Friday, October 2nd. Finally, Lifesci Capital lowered shares of Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: A valuation analysis argues that Liquidia could be substantially undervalued, potentially by as much as 74%, if YUTREPIA retains meaningful market access despite the patent dispute. The analysis highlights the company’s commercial revenue potential and ongoing investor interest. Liquidia Could Be 74% Undervalued
• Positive Sentiment: Analyst coverage remains constructive. HC Wainwright reiterated a Buy rating and a $58 price target, well above the recent trading level, while another report described Liquidia among bullishly viewed healthcare stocks. Analysts Are Bullish on Liquidia
• Neutral Sentiment: Institutional ownership data showed more funds adding than reducing positions in the latest quarter, including substantial purchases by BlackRock and T. Rowe Price. However, insider activity was heavily weighted toward sales, which may temper that signal.
• Negative Sentiment: A federal court found two patent claims valid and infringed in connection with YUTREPIA’s use for pulmonary hypertension associated with interstitial lung disease. Liquidia plans to remove that indication from the product label, raising concerns about access, future revenue and the company’s prior forecast of more than $1 billion in 2027 net revenue. Liquidia Falls as Patent Ruling Overhang Continues
• Negative Sentiment: Several law firms announced shareholder investigations seeking potential securities claims tied to the patent ruling and Liquidia’s revenue projections. Such notices can increase litigation uncertainty and add selling pressure. Levi and Korsinsky Liquidia Investigation
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including Q3 2026 EPS to $0.76 from $1.01 and FY2026 EPS to $2.72 from $3.44. The firm maintained its Buy rating, but the cuts reflect greater uncertainty around YUTREPIA’s earnings potential. HC Wainwright Liquidia Earnings Estimates

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the business. WINTON GROUP Ltd purchased a new position in Liquidia during the 2nd quarter valued at $335,000. Arizona State Retirement System raised its holdings in Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after purchasing an additional 900 shares in the last quarter. Nykredit A S purchased a new stake in shares of Liquidia in the 2nd quarter worth about $177,000. Corient Private Wealth LP purchased a new stake in shares of Liquidia in the 2nd quarter worth about $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Liquidia during the 2nd quarter valued at about $1,236,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).